Yenidoğanlarda Persistan Pulmoner Hipertansiyon Risk Faktörleri, Klinik ve Prognozun Belirlenmesi

Yıl 2022, , 110 - 116, 09.09.2022

Beril Yaşa , Emre Dincer , Aslan Babayiğit Seda Yılmaz Semerci , Şeyma Memur , Özge Sağlam , İlker Gönen , Halime Sema Can Büker , Serhat Özkan Helen Bornaun Kazım Öztarhan , Merih Çetinkaya

https://doi.org/10.26650/jchild.2022.1113770

Öz

Amaç: Yenidoğanın persistan pulmoner hipertansiyonu (PPHN) geçiş döneminde pulmoner vasküler direncin yüksek kalması sonucu gelişen önemli morbidite ve mortalite ile sonlanabilen ciddi bir klinik durumdur. Bu çalışmada PPHN tanısıyla izlenen yenidoğan bebeklerde risk faktörlerinin belirlenmesi, klinik prognozun, mortalite ve morbiditelerin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: Retrospektif gözlemsel bu çalışmada Ocak 2017-Ocak 2019 tarihileri arasında Yenidoğan Yoğun Bakım Ünitesinde (YYBÜ) PPHN tanısıyla izlenen bebeklerin verileri hastane kayıtlarından incelenmiş, PPHN etiyolojisi, bebeklerin klinik bulguları, morbiditeler ve mortalite değerlendirilmiştir. Bulgular: İki senelik çalışma periyodunda toplam 29.650 bebek dünyaya geldi, bebeklerin 920’si YYBÜ’de yatırıldı ve 50 bebekte PPHN saptandı. PPHN gelişen olguların %66’sı prematüre ve %52’si kız idi. PPHN gelişimi ile ilişkilendirilen en sık etiyolojik faktör term bebeklerde konjenital pnömoni (%65) iken, preterm bebeklerde respiratuar distres sendromu (%100) idi. Her iki grupta da en sık ikinci etiyolojik faktör perinatal asfiksi idi. Patent duktus arteriyozus, intraventriküler kanama, nekrotizan enterokolit ve bronkopulmoner displazi gibi morbiditeler PPHN gelişen preterm bebeklerde daha sık görülürken, mortalite oranı da preterm grupta daha yüksek bulundu. Tartışma: Persistan pulmoner hipertansiyon, uygun kardiyorespiratuvar destek ve güncel tedavilere rağmen yüksek neonatal mortaliteye sahip ciddi bir durumdur. Pulmoner hipertansiyon gelişimi ve mortalite üzerine etkili risk faktörlerinin belirlenmesi ile mortalite ve ilişkili morbiditelerin azaltılabileceği düşünülmektedir.

Anahtar Kelimeler

persistan pulmoner hipertansiyon, yenidoğan, preterm

Destekleyen Kurum

Destekleyen kurum yoktur

Risk Factors for Persistent Pulmonary Hypertension of the Newborn and Determining the Clinical Prognosis

Öz

Objective: Persistent pulmonary hypertension of the newborn (PPHN) is a serious clinical condition that developed through the persistence of high pulmonary vascular resistance during the transition period and results in severe morbidities and mortality. This study aims to determine the risk factors for developing PPHN and to evaluate the prognosis, morbidities, and mortality. Materials and Method: This retrospective study was conducted between January 2017 and January 2019. Hospital records of infants who needed neonatal intensive care were evaluated retrospectively in terms of etiological causes of PPHN, clinical prognosis of neonates, morbidities, and mortality rates. Results: A total of 29,650 infants were born during the 2-year study period, 920 of whom were admitted to a neonatal intensive care unit, of which 50 developed PPHN. Of the infants who developed PPHN, 66% were preterm and 52% were female. The most common etiology related to developing PPHN is congenital pneumonia (65%) in term infants and respiratory distress syndrome (100%) in preterm infants. The second most common etiology is perinatal asphyxia for both term and preterm infants. Morbidities such as patent ductus arteriosus, intraventricular hemorrhage, necrotizing enterocolitis, and bronchopulmonary dysplasia were higher in the preterm group, with mortality rates also being significantly higher in preterm infants. Conclusion: Persistent pulmonary hypertension of the newborn is a serious clinical condition that may result in high neonatal mortality even when appropriate cardiopulmonary support is given. Mortality and mortality-related morbidities are thought to be able to be decreased by defining the risk factors for developing PPHN.

Anahtar Kelimeler

Persistent pulmonary hypertension, neonates, preterm

Kaynakça

• 1. Steinhorn RH. Neonatal Pulmonary Hypertension. Pediatr Crit Care Med 2010;11(2 Suppl):S79-S84. google scholar
• 2. Hooper SB, Te Pas AB, Lang J, et al. Cardiovascular transition at birth: a physiological sequence. Pediatr Res 2015;77:608-14. google scholar
• 3. Aktas SY, Diniz G, Ortac R, Aktas EÖ. Pulmonary hypertension grading in the neonate: Pediatric autopsy series compared with etiology of lung disease. Aegean Pathology Journal 2004;1:76-80. google scholar
• 4. Jain A, McNamara PJ. Persistent pulmonary hypertension of the hewborn: Advances in diagnosis and treatment. Semin Fetal Neonatal Med 2015;20(4):262-71. google scholar
• 5. Lakshminrusimha S, Keszler M. Persistent Pulmonary Hypertension of the Newborn. Neoreviews 2015;16;e680. google scholar
• 6. de Boode WP, Singh Y, Molnar Z, Schubert U, Savoia M, Sehgal A et al. Application of neonatologist performed echocardiography in the assessment and management of persistent pulmonary hypertension of the newborn. Pediatric Research 2018;84:68-77. google scholar
• 7. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CC, Korones SB, Stevenson DK et al. Persistant pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatr 2000;105:14-20. google scholar
• 8. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS). J Pediatr 2000;136:611-7. google scholar
• 9. Ozkan H, Erdeve O, Kutman HGK. Turkish Neonatal Society guideline on the management of respiratory distress syndrome and surfactant treatment. Turk Pediatri Ars 2018;53(S1):S45-S54. Doi: 10.5152/TurkPediatriArs.2018.01806 google scholar
• 10. Köksal N, Aygün C, Uras N. Turkish Neonatal Society guideline on the management of patent ductus arteriosus in preterm infants. Turk Pediatri Ars 2018; 53(S1):S76-87. google scholar
• 11. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163(7):1723-9.doi: 10.1164/ajrccm.163.7. 2011060 google scholar
• 12. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986;33(1):179-201. doi: 10.1016/s0031-3955(16) 34975-6 google scholar
• 13. Volpe JJ. Intracranial hemorrhage: germinal matrix-intraventricular hemorrhage of the premature infant. In: Volpe JJ, editor. Neurology of the newborn. 5th edition. Philadelphia: Elsevier; 2008. Pp. 517588. google scholar
• 14. International Committee for the Classification of of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Opthalmol 2005;123:991-9. Doi:10.1001/archopht.123.7.991 google scholar
• 15. Satar M, Arısoy AE, Celik IH. Turkish Neonatal Society guideline on neonatal infections-diagnosis and treatment. Turk Pediatri Ars 2018;53(S1):S88-S100. Doi: 10.5152/TurkPediatriArs.2018.01809. google scholar
• 16. Fuloria M, Aschner JL. Persistent pulmonary hypertension of the newborn. Seminars in Fetal & Neonatal Medicine (2017), http:// dx.doi.org/10.1016/j.siny.2017.03.004 google scholar
• 17. Steurer MA, Jelliffe-Paeloeski LL, Baer RJ, Partridge JC, Rogers EE, Keller RL. Persistent pulmonary hypertensionof the newborn in late preterm and term infants in California. Pediatrics 2017;139:1:e20262265. google scholar
• 18. Lapointe A, Barrington KJ. Pulmonary hypertension and asphyxiated newborn. J Pediatr 2011;158(2):e19-24. google scholar
• 19. Kumar VH, Hutchison AA, Lakshminrusimha S, Morin FC III, Wynn RJ, Ryan RM. Characteristics of pulmonary hypertension in preterm neonates. J Perinatol 2007;27(4):214-9. google scholar
• 20. O’Connor MG, Cornfield DN, Austin ED. Pulmonary hypertension in the premature infant: A challenging comorbidity in a vulnerable population. Curr Opin Pediatr 2016;28(3):324-30. google scholar 21. Farrow K, Steinhorn RH. Pulmonary hypertension in premature infants, sharpening the tools of detection. Am J Resp Crit Care Med 2015;191(1):12-3. google scholar
• 22. Naumburg E, Söderström L. Increased risk of pulmonary hypertension following premature birth. BMC Pediatrics 2019;19:288 google scholar
• 23. Nair J, Lakshminrushima S. Update on PPHN: mechanisms and treatment. Semin Perinatol 2014;38(2):78-91. google scholar
• 24. Nakanishi H, Suenaga H, Uchiyama A, Kusuda S, on behalf of the Neonatal Research Network, Japan. Persistent pulmonary hypertension of the newborn in extremely preterm infants: A Japanese cohort study. Arch Dis Child Fetal Neonatal Ed 2018;103:F554-F561. google scholar
• 25. Weismann CG, Asnes JD, BAzzy-Asaad A, Tolomeo C, Ehrenkranz RA, Bizzarro MJ. Pulmonary hypertension in preterm infants: results of prospective screening program. Journal of Perinatology 2017;37:572-7. google scholar
• 26. Seth SA, Soraisham AS, Harabor A. Risk factors and outcomes of early pulmonary hypertension in preterm infants. The Journal of Maternal Fetal & Neonatal Medicine, DOI: 10.1080/12767058.2017.129 google scholar
• 27. Razzaq Athar, Quddusi AI, Nizami N. Risk factors and mortality among newborns with persistent pulmonary hypertension. Pak J Med Sci 2013;29(5):1099-104. google scholar
• 28. Bifano EM, Pfannenstiel A. Duration of hyperventilation and outcome in infants with persistent pulmonary hypertension. Pediatrics 1988;81(5):657-61. google scholar
• 29. Hendricks Munoz KD, Walton JP. Hearing loss in infants with persistent fetal circulation. Pediatrics 1988;81(5):650-6. google scholar
• 30. Davidson D, Barefield ES, Kattwinkel J, et al; The I-NO/PPHN Study Group. Inhaled nitric oxide fort he early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double masked, placebo controlled, dose response, multicenter study. Pediatrics 1998;101(3):325-34. google scholar
• 31. Clark RH, Kueser TJ, Walker MW, et al; Clinical Inhaled Nitric Oxide Research Group. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med. 2000;342(7):469-74. google scholar
• 32. Hosono S, Ohno T, Kimoto H, Shimizu M, Takahashi S, Harada K. Developmental outcomes in persistent pulmonary hypertension treated with nitric oxide therapy. Pediatr Int 2009;51(1):79-83. google scholar
• 33. Kumar, P., Committee on F, Newborn, American Academy of P. Use of inhaled nitric oxide in preterm infants. Pediatrics 2014;133:164-70. google scholar
• 34. Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 1, CD000509 (2017). google scholar
• 35. Cole FS, Alleyne C, Barks JD, Boyle RJ, CArroll JL, Dokken D et al. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics 2011;127(2):363-9. google scholar
• 36. Pandya KA, Puligandla PS. Pulmonary hypertension managementin neonates. Semi Pediatr Surg 2015;24(1):12-6. google scholar
• 37. Radicioni M, Bruni A, Camerini P. Combination therapy for life threatening pulmonary hypertension in a premature infant: first report on bosentan use. Eur J Pediatr 2011;170(8):1075-8. google scholar
• 38. Rao S, Bartle D, Patole S. Current and future therapeutic options for persistent pulmonary hypertension in the newborn. Expert Rev Cardiovasc Ther 2010;8(6):845-62. google scholar
• 39. Puthiyachirakkal M, Mhanna MJ. Pathophysiology, management and outcome of persistent pulmonary hypertension of the newborn: a clinical review. Front Pediatr 2013;1:23. google scholar
• 40. Ellington M Jr, O’Reilly D, Allred EN, et al. Child health status, neurodevelopmental outcome and parental satisfaction in a randomized, controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 2001;107:1351-6. google scholar